Rasika Mathias
Concepts (800)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genome-Wide Association Study | 93 | 2026 | 1537 | 5.000 |
Why?
| | Polymorphism, Single Nucleotide | 105 | 2026 | 2240 | 4.480 |
Why?
| | Genetic Predisposition to Disease | 71 | 2026 | 2488 | 3.940 |
Why?
| | Peanut Hypersensitivity | 7 | 2026 | 143 | 3.650 |
Why?
| | Asthma | 51 | 2025 | 1800 | 3.510 |
Why?
| | Arachis | 6 | 2026 | 108 | 2.560 |
Why?
| | Whole Genome Sequencing | 29 | 2026 | 183 | 2.520 |
Why?
| | Dermatitis, Atopic | 9 | 2023 | 319 | 2.170 |
Why?
| | Precision Medicine | 22 | 2026 | 462 | 2.060 |
Why?
| | Food Hypersensitivity | 4 | 2023 | 165 | 1.950 |
Why?
| | Genetic Variation | 31 | 2025 | 996 | 1.940 |
Why?
| | Fatty Acid Desaturases | 12 | 2021 | 32 | 1.860 |
Why?
| | Genome, Human | 20 | 2025 | 431 | 1.750 |
Why?
| | Immunoglobulin E | 18 | 2021 | 315 | 1.720 |
Why?
| | Platelet Aggregation | 12 | 2021 | 99 | 1.650 |
Why?
| | Genotype | 42 | 2025 | 1879 | 1.560 |
Why?
| | Induced Pluripotent Stem Cells | 4 | 2021 | 269 | 1.560 |
Why?
| | Allergens | 6 | 2026 | 390 | 1.540 |
Why?
| | Exome | 14 | 2022 | 233 | 1.520 |
Why?
| | Genomics | 18 | 2025 | 853 | 1.450 |
Why?
| | Immunoglobulin G | 4 | 2026 | 901 | 1.450 |
Why?
| | Multifactorial Inheritance | 6 | 2025 | 243 | 1.430 |
Why?
| | Blood Platelets | 12 | 2022 | 382 | 1.390 |
Why?
| | Kaposi Varicelliform Eruption | 4 | 2021 | 21 | 1.320 |
Why?
| | Quantitative Trait Loci | 19 | 2026 | 388 | 1.310 |
Why?
| | Alleles | 22 | 2023 | 907 | 1.310 |
Why?
| | Genetics, Population | 16 | 2025 | 226 | 1.270 |
Why?
| | Megakaryocytes | 3 | 2021 | 34 | 1.200 |
Why?
| | Phenotype | 51 | 2025 | 3206 | 1.170 |
Why?
| | Humans | 251 | 2026 | 146342 | 1.140 |
Why?
| | Genetic Loci | 18 | 2021 | 273 | 1.120 |
Why?
| | Fatty Acids, Omega-6 | 5 | 2017 | 47 | 1.100 |
Why?
| | Nasal Mucosa | 3 | 2025 | 112 | 1.030 |
Why?
| | Multigene Family | 9 | 2021 | 210 | 0.990 |
Why?
| | Coronary Artery Disease | 11 | 2025 | 751 | 0.970 |
Why?
| | Receptors, Cell Surface | 8 | 2024 | 371 | 0.930 |
Why?
| | DNA Methylation | 7 | 2025 | 725 | 0.930 |
Why?
| | Transcriptome | 5 | 2025 | 1068 | 0.920 |
Why?
| | Gene Frequency | 23 | 2024 | 496 | 0.900 |
Why?
| | Gene Expression Regulation | 11 | 2025 | 2599 | 0.900 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 13 | 2026 | 103 | 0.890 |
Why?
| | Linoleic Acid | 6 | 2023 | 44 | 0.840 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2024 | 25 | 0.820 |
Why?
| | Hypersensitivity, Immediate | 2 | 2023 | 41 | 0.790 |
Why?
| | Male | 120 | 2026 | 73396 | 0.770 |
Why?
| | Genetic Linkage | 14 | 2022 | 271 | 0.770 |
Why?
| | Models, Genetic | 14 | 2025 | 540 | 0.770 |
Why?
| | HLA-DQ alpha-Chains | 2 | 2022 | 17 | 0.730 |
Why?
| | Female | 120 | 2026 | 79499 | 0.720 |
Why?
| | Chromosome Mapping | 16 | 2021 | 508 | 0.720 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 11 | 2021 | 928 | 0.700 |
Why?
| | 2S Albumins, Plant | 1 | 2022 | 31 | 0.690 |
Why?
| | Gene Expression | 4 | 2025 | 1463 | 0.690 |
Why?
| | Linkage Disequilibrium | 19 | 2022 | 260 | 0.690 |
Why?
| | Gene-Environment Interaction | 4 | 2026 | 190 | 0.680 |
Why?
| | Mosaicism | 4 | 2025 | 67 | 0.680 |
Why?
| | Antigens, Plant | 1 | 2022 | 55 | 0.680 |
Why?
| | Nucleotide Transport Proteins | 1 | 2021 | 1 | 0.670 |
Why?
| | High-Throughput Nucleotide Sequencing | 6 | 2019 | 539 | 0.670 |
Why?
| | Middle Aged | 72 | 2026 | 36619 | 0.670 |
Why?
| | Frailty | 4 | 2025 | 208 | 0.660 |
Why?
| | Antibody Formation | 1 | 2022 | 290 | 0.630 |
Why?
| | von Willebrand Factor | 6 | 2025 | 84 | 0.630 |
Why?
| | Platelet Function Tests | 3 | 2021 | 37 | 0.620 |
Why?
| | Genetic Association Studies | 13 | 2024 | 379 | 0.610 |
Why?
| | Herpesvirus 1, Human | 1 | 2021 | 87 | 0.610 |
Why?
| | Lung | 10 | 2022 | 4122 | 0.600 |
Why?
| | Pedigree | 8 | 2025 | 512 | 0.580 |
Why?
| | Lipids | 8 | 2023 | 714 | 0.580 |
Why?
| | Adult | 68 | 2025 | 41087 | 0.570 |
Why?
| | Open Reading Frames | 3 | 2021 | 130 | 0.550 |
Why?
| | Fibrinogen | 7 | 2024 | 182 | 0.530 |
Why?
| | Diabetes Mellitus, Type 2 | 11 | 2026 | 2623 | 0.520 |
Why?
| | Alzheimer Disease | 1 | 2023 | 641 | 0.490 |
Why?
| | Chromosomes, Human, Pair 11 | 5 | 2014 | 61 | 0.480 |
Why?
| | Computational Biology | 5 | 2025 | 678 | 0.480 |
Why?
| | Human Migration | 1 | 2016 | 26 | 0.480 |
Why?
| | Telomere | 6 | 2026 | 300 | 0.480 |
Why?
| | Pulmonary Emphysema | 3 | 2014 | 276 | 0.480 |
Why?
| | Case-Control Studies | 21 | 2025 | 3647 | 0.480 |
Why?
| | Risk Factors | 24 | 2025 | 10921 | 0.470 |
Why?
| | Platelet Activation | 4 | 2018 | 99 | 0.460 |
Why?
| | Gene Flow | 1 | 2016 | 91 | 0.460 |
Why?
| | Evolution, Molecular | 3 | 2019 | 502 | 0.440 |
Why?
| | Software | 5 | 2024 | 676 | 0.430 |
Why?
| | Haplotypes | 14 | 2025 | 506 | 0.420 |
Why?
| | Blood Proteins | 3 | 2025 | 239 | 0.420 |
Why?
| | Geography | 2 | 2016 | 187 | 0.420 |
Why?
| | RNA | 1 | 2021 | 926 | 0.410 |
Why?
| | Polymorphism, Genetic | 11 | 2017 | 612 | 0.410 |
Why?
| | Aging | 5 | 2025 | 1996 | 0.400 |
Why?
| | HLA-B7 Antigen | 1 | 2013 | 7 | 0.400 |
Why?
| | Fatty Acids, Unsaturated | 4 | 2020 | 97 | 0.400 |
Why?
| | Diet | 4 | 2023 | 1273 | 0.390 |
Why?
| | Desensitization, Immunologic | 2 | 2026 | 91 | 0.390 |
Why?
| | Biomarkers | 8 | 2025 | 4340 | 0.390 |
Why?
| | Bronchial Hyperreactivity | 1 | 2014 | 104 | 0.380 |
Why?
| | Quantitative Trait, Heritable | 6 | 2021 | 119 | 0.380 |
Why?
| | Epigenesis, Genetic | 6 | 2024 | 712 | 0.380 |
Why?
| | Interferon-gamma | 3 | 2015 | 781 | 0.370 |
Why?
| | Hypersensitivity | 4 | 2024 | 253 | 0.360 |
Why?
| | Mutation | 10 | 2026 | 4093 | 0.360 |
Why?
| | Airway Obstruction | 1 | 2014 | 152 | 0.350 |
Why?
| | Child | 30 | 2025 | 22693 | 0.350 |
Why?
| | Immunity, Cellular | 1 | 2013 | 277 | 0.340 |
Why?
| | Fatty Acids, Omega-3 | 3 | 2021 | 145 | 0.340 |
Why?
| | Chromosome Aberrations | 3 | 2026 | 167 | 0.330 |
Why?
| | Likelihood Functions | 5 | 2012 | 138 | 0.330 |
Why?
| | Aged | 36 | 2026 | 26432 | 0.330 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2011 | 66 | 0.330 |
Why?
| | Leukocytes | 4 | 2023 | 301 | 0.330 |
Why?
| | United States | 30 | 2026 | 16136 | 0.330 |
Why?
| | Cardiovascular Diseases | 8 | 2025 | 2219 | 0.330 |
Why?
| | Dyslipidemias | 3 | 2016 | 184 | 0.320 |
Why?
| | Mendelian Randomization Analysis | 3 | 2024 | 68 | 0.320 |
Why?
| | RNA, Long Noncoding | 2 | 2023 | 174 | 0.310 |
Why?
| | Liver | 7 | 2024 | 1864 | 0.310 |
Why?
| | DNA, Mitochondrial | 2 | 2023 | 212 | 0.310 |
Why?
| | Diabetes Mellitus | 4 | 2023 | 1101 | 0.300 |
Why?
| | Cell Adhesion Molecules | 2 | 2024 | 180 | 0.300 |
Why?
| | Genome | 4 | 2022 | 307 | 0.300 |
Why?
| | Factor VIII | 2 | 2024 | 107 | 0.300 |
Why?
| | Cohort Studies | 15 | 2021 | 6077 | 0.300 |
Why?
| | Adolescent | 29 | 2023 | 22557 | 0.300 |
Why?
| | Organ Specificity | 2 | 2021 | 307 | 0.280 |
Why?
| | Computer Simulation | 8 | 2024 | 1014 | 0.280 |
Why?
| | Healthcare Disparities | 3 | 2025 | 733 | 0.280 |
Why?
| | Smoking | 6 | 2018 | 1486 | 0.280 |
Why?
| | Pharmacogenetics | 2 | 2020 | 176 | 0.270 |
Why?
| | Genetic Pleiotropy | 3 | 2019 | 37 | 0.270 |
Why?
| | Adaptation, Physiological | 1 | 2012 | 568 | 0.270 |
Why?
| | Dietary Fats | 1 | 2010 | 307 | 0.270 |
Why?
| | Germ-Line Mutation | 3 | 2025 | 180 | 0.270 |
Why?
| | Atherosclerosis | 2 | 2025 | 410 | 0.260 |
Why?
| | HLA-DQ beta-Chains | 2 | 2021 | 58 | 0.260 |
Why?
| | Arachidonic Acid | 6 | 2015 | 101 | 0.260 |
Why?
| | Point Mutation | 2 | 2025 | 232 | 0.260 |
Why?
| | Gene Regulatory Networks | 2 | 2024 | 319 | 0.260 |
Why?
| | Fasting | 2 | 2022 | 280 | 0.250 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2013 | 931 | 0.250 |
Why?
| | Blood Glucose | 5 | 2026 | 2360 | 0.250 |
Why?
| | Body Height | 4 | 2015 | 205 | 0.250 |
Why?
| | Loss of Function Mutation | 3 | 2021 | 48 | 0.240 |
Why?
| | Restless Legs Syndrome | 1 | 2006 | 20 | 0.240 |
Why?
| | Aspirin | 4 | 2018 | 405 | 0.240 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2006 | 24 | 0.240 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2006 | 57 | 0.240 |
Why?
| | Computer Graphics | 1 | 2006 | 41 | 0.230 |
Why?
| | Schistosoma japonicum | 2 | 2017 | 36 | 0.230 |
Why?
| | Lipoprotein Lipase | 1 | 2006 | 55 | 0.230 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2017 | 752 | 0.230 |
Why?
| | Metabolic Syndrome | 4 | 2025 | 364 | 0.230 |
Why?
| | Biological Specimen Banks | 3 | 2024 | 137 | 0.220 |
Why?
| | Health Status Disparities | 3 | 2025 | 322 | 0.220 |
Why?
| | Serine | 1 | 2006 | 142 | 0.220 |
Why?
| | Helminthiasis | 2 | 2017 | 11 | 0.220 |
Why?
| | Endophenotypes | 1 | 2025 | 37 | 0.220 |
Why?
| | Genomic Structural Variation | 1 | 2025 | 13 | 0.220 |
Why?
| | von Willebrand Diseases | 1 | 2025 | 28 | 0.220 |
Why?
| | Hematopoietic Stem Cells | 3 | 2024 | 432 | 0.220 |
Why?
| | Hematopoiesis | 2 | 2023 | 195 | 0.220 |
Why?
| | Membrane Proteins | 7 | 2017 | 1130 | 0.220 |
Why?
| | Models, Statistical | 7 | 2021 | 669 | 0.210 |
Why?
| | Chromosomes, Human, Y | 1 | 2025 | 36 | 0.210 |
Why?
| | Cholesterol, HDL | 4 | 2016 | 201 | 0.210 |
Why?
| | Consanguinity | 2 | 2005 | 50 | 0.210 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2025 | 40 | 0.210 |
Why?
| | Child, Preschool | 17 | 2026 | 11913 | 0.210 |
Why?
| | Chromosome Deletion | 1 | 2025 | 127 | 0.210 |
Why?
| | Kininogens | 1 | 2024 | 6 | 0.210 |
Why?
| | Chromosomes, Human, Pair 16 | 3 | 2021 | 36 | 0.210 |
Why?
| | Inflammation | 6 | 2024 | 2919 | 0.210 |
Why?
| | Lectins, C-Type | 1 | 2024 | 61 | 0.200 |
Why?
| | Interleukin-13 | 3 | 2023 | 149 | 0.200 |
Why?
| | Forced Expiratory Volume | 4 | 2019 | 451 | 0.200 |
Why?
| | Young Adult | 13 | 2022 | 14330 | 0.200 |
Why?
| | Blood Pressure | 6 | 2022 | 1765 | 0.200 |
Why?
| | Telomere Homeostasis | 1 | 2024 | 35 | 0.200 |
Why?
| | Chemokines, CC | 2 | 2014 | 33 | 0.200 |
Why?
| | Liver Cirrhosis | 2 | 2017 | 278 | 0.200 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2786 | 0.200 |
Why?
| | Leukemia | 1 | 2026 | 246 | 0.200 |
Why?
| | Population Groups | 3 | 2019 | 55 | 0.200 |
Why?
| | Fibronectins | 1 | 2024 | 136 | 0.200 |
Why?
| | Menopause, Premature | 1 | 2023 | 12 | 0.190 |
Why?
| | Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 2 | 2022 | 3 | 0.190 |
Why?
| | Barbados | 8 | 2013 | 8 | 0.190 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 2 | 2017 | 31 | 0.190 |
Why?
| | Respiration | 2 | 2014 | 208 | 0.190 |
Why?
| | Administration, Oral | 1 | 2026 | 872 | 0.190 |
Why?
| | Blood Cells | 1 | 2022 | 38 | 0.190 |
Why?
| | Frameshift Mutation | 1 | 2022 | 32 | 0.190 |
Why?
| | Erythrocytes | 2 | 2021 | 750 | 0.190 |
Why?
| | Proteomics | 3 | 2024 | 1203 | 0.190 |
Why?
| | Interleukin-4 | 2 | 2023 | 207 | 0.180 |
Why?
| | Regulatory Sequences, Nucleic Acid | 2 | 2025 | 90 | 0.180 |
Why?
| | Chromosomes, Human, X | 2 | 2021 | 76 | 0.180 |
Why?
| | Promoter Regions, Genetic | 6 | 2023 | 1242 | 0.180 |
Why?
| | Telomere Shortening | 1 | 2022 | 20 | 0.180 |
Why?
| | Eczema | 1 | 2023 | 66 | 0.180 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 370 | 0.180 |
Why?
| | Proteome | 2 | 2024 | 520 | 0.180 |
Why?
| | Nerve Tissue Proteins | 5 | 2022 | 597 | 0.180 |
Why?
| | Acute Coronary Syndrome | 2 | 2016 | 299 | 0.170 |
Why?
| | Coronary Disease | 2 | 2019 | 380 | 0.170 |
Why?
| | Gastritis | 1 | 2023 | 117 | 0.170 |
Why?
| | Genetic Heterogeneity | 3 | 2016 | 67 | 0.170 |
Why?
| | Enteritis | 1 | 2023 | 105 | 0.170 |
Why?
| | Pseudomonas Infections | 2 | 2015 | 229 | 0.170 |
Why?
| | HLA-A2 Antigen | 1 | 2021 | 36 | 0.170 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2025 | 1150 | 0.170 |
Why?
| | Dinoprostone | 1 | 2022 | 179 | 0.170 |
Why?
| | Patient Compliance | 1 | 2025 | 589 | 0.170 |
Why?
| | Americas | 1 | 2021 | 27 | 0.170 |
Why?
| | Spain | 1 | 2021 | 50 | 0.170 |
Why?
| | Aged, 80 and over | 11 | 2026 | 8391 | 0.170 |
Why?
| | Infant | 10 | 2026 | 10114 | 0.170 |
Why?
| | DNA Copy Number Variations | 2 | 2020 | 192 | 0.170 |
Why?
| | Cyclooxygenase Inhibitors | 2 | 2014 | 82 | 0.170 |
Why?
| | Pulmonary Medicine | 2 | 2019 | 78 | 0.160 |
Why?
| | Peru | 1 | 2021 | 61 | 0.160 |
Why?
| | Leishmaniasis, Visceral | 1 | 2001 | 24 | 0.160 |
Why?
| | Gene Ontology | 1 | 2021 | 55 | 0.160 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2021 | 83 | 0.160 |
Why?
| | Odds Ratio | 7 | 2019 | 1077 | 0.160 |
Why?
| | Glutathione Transferase | 1 | 2021 | 92 | 0.160 |
Why?
| | Cytokines | 4 | 2023 | 2081 | 0.160 |
Why?
| | DNA-Binding Proteins | 4 | 2023 | 1468 | 0.160 |
Why?
| | Risk | 7 | 2019 | 920 | 0.160 |
Why?
| | gamma-Linolenic Acid | 1 | 2020 | 2 | 0.160 |
Why?
| | HLA-DQ Antigens | 1 | 2021 | 171 | 0.160 |
Why?
| | Immunologic Factors | 1 | 2022 | 244 | 0.160 |
Why?
| | Chromosomes, Human, Pair 19 | 3 | 2012 | 28 | 0.160 |
Why?
| | Receptors, Nicotinic | 2 | 2013 | 337 | 0.160 |
Why?
| | Social Determinants of Health | 1 | 2025 | 317 | 0.160 |
Why?
| | Soybean Oil | 1 | 2020 | 15 | 0.160 |
Why?
| | Algorithms | 7 | 2025 | 1849 | 0.160 |
Why?
| | Energy Intake | 1 | 2023 | 507 | 0.160 |
Why?
| | Base Sequence | 4 | 2021 | 2123 | 0.160 |
Why?
| | Lipid Metabolism | 2 | 2021 | 533 | 0.160 |
Why?
| | Plant Oils | 1 | 2020 | 33 | 0.160 |
Why?
| | Amish | 1 | 2020 | 7 | 0.150 |
Why?
| | beta-Globins | 1 | 2019 | 8 | 0.150 |
Why?
| | Platelet Aggregation Inhibitors | 2 | 2018 | 499 | 0.150 |
Why?
| | Cholesterol, LDL | 5 | 2022 | 363 | 0.150 |
Why?
| | Indians, North American | 2 | 2021 | 527 | 0.150 |
Why?
| | Thrombosis | 5 | 2024 | 398 | 0.150 |
Why?
| | Hemorrhage | 1 | 2025 | 825 | 0.150 |
Why?
| | Genomic Instability | 1 | 2020 | 64 | 0.150 |
Why?
| | Mutation, Missense | 2 | 2023 | 334 | 0.150 |
Why?
| | Homozygote | 3 | 2016 | 197 | 0.150 |
Why?
| | Occipital Lobe | 1 | 2019 | 30 | 0.150 |
Why?
| | 8,11,14-Eicosatrienoic Acid | 3 | 2020 | 6 | 0.150 |
Why?
| | Th2 Cells | 4 | 2023 | 179 | 0.150 |
Why?
| | HLA-DRB1 Chains | 1 | 2020 | 109 | 0.150 |
Why?
| | Parietal Lobe | 1 | 2019 | 62 | 0.140 |
Why?
| | Eicosanoids | 2 | 2022 | 58 | 0.140 |
Why?
| | Tissue Plasminogen Activator | 1 | 2021 | 245 | 0.140 |
Why?
| | Diabetic Nephropathies | 1 | 2023 | 320 | 0.140 |
Why?
| | Photometry | 1 | 2019 | 3 | 0.140 |
Why?
| | Chromosomes, Human, Pair 12 | 4 | 2019 | 22 | 0.140 |
Why?
| | Genes, Mitochondrial | 1 | 2018 | 14 | 0.140 |
Why?
| | Chromatography, Gas | 1 | 2019 | 31 | 0.140 |
Why?
| | Flame Retardants | 1 | 2019 | 10 | 0.140 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2026 | 697 | 0.140 |
Why?
| | Sleep Medicine Specialty | 1 | 2019 | 12 | 0.140 |
Why?
| | Plasticizers | 1 | 2019 | 18 | 0.140 |
Why?
| | Brazil | 6 | 2017 | 179 | 0.140 |
Why?
| | Receptors, Immunologic | 3 | 2022 | 210 | 0.140 |
Why?
| | Chromosomes, Human, Pair 6 | 2 | 2025 | 51 | 0.140 |
Why?
| | Temporal Lobe | 1 | 2019 | 112 | 0.140 |
Why?
| | Chromosomes, Human, Pair 18 | 1 | 2018 | 8 | 0.140 |
Why?
| | Metabolism | 1 | 2018 | 44 | 0.140 |
Why?
| | India | 3 | 2009 | 213 | 0.140 |
Why?
| | Clinical Trials as Topic | 2 | 2022 | 1064 | 0.140 |
Why?
| | Databases, Genetic | 4 | 2021 | 239 | 0.140 |
Why?
| | Metabolomics | 2 | 2024 | 738 | 0.140 |
Why?
| | Smad2 Protein | 1 | 2018 | 37 | 0.140 |
Why?
| | Eosinophilic Esophagitis | 1 | 2023 | 333 | 0.140 |
Why?
| | Brain | 2 | 2023 | 2991 | 0.140 |
Why?
| | Computer Communication Networks | 1 | 2018 | 30 | 0.140 |
Why?
| | Family | 4 | 2012 | 690 | 0.140 |
Why?
| | Hominidae | 1 | 2019 | 89 | 0.140 |
Why?
| | Sex Characteristics | 3 | 2014 | 801 | 0.140 |
Why?
| | Frontal Lobe | 1 | 2019 | 159 | 0.140 |
Why?
| | Exons | 3 | 2016 | 361 | 0.140 |
Why?
| | Telomerase | 2 | 2024 | 252 | 0.130 |
Why?
| | Lipopolysaccharide Receptors | 2 | 2010 | 88 | 0.130 |
Why?
| | Comorbidity | 1 | 2023 | 1665 | 0.130 |
Why?
| | Molecular Targeted Therapy | 1 | 2020 | 447 | 0.130 |
Why?
| | Africa | 2 | 2020 | 119 | 0.130 |
Why?
| | Immunotherapy | 1 | 2022 | 671 | 0.130 |
Why?
| | Cross-Sectional Studies | 7 | 2025 | 5899 | 0.130 |
Why?
| | Noncommunicable Diseases | 1 | 2017 | 21 | 0.130 |
Why?
| | Organophosphates | 1 | 2019 | 179 | 0.130 |
Why?
| | Quality Control | 4 | 2021 | 163 | 0.130 |
Why?
| | Hyaluronoglucosaminidase | 1 | 2017 | 8 | 0.130 |
Why?
| | Information Storage and Retrieval | 1 | 2018 | 121 | 0.130 |
Why?
| | Molecular Epidemiology | 3 | 2013 | 74 | 0.130 |
Why?
| | Animals | 20 | 2023 | 38106 | 0.120 |
Why?
| | Rural Health | 1 | 1997 | 87 | 0.120 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 745 | 0.120 |
Why?
| | Sequence Analysis, DNA | 6 | 2018 | 771 | 0.120 |
Why?
| | Interleukin-1 Receptor-Like 1 Protein | 1 | 2017 | 22 | 0.120 |
Why?
| | Endemic Diseases | 1 | 2017 | 34 | 0.120 |
Why?
| | Insulin Resistance | 1 | 2025 | 1247 | 0.120 |
Why?
| | Schistosoma mansoni | 1 | 2017 | 45 | 0.120 |
Why?
| | Scavenger Receptors, Class B | 1 | 2016 | 14 | 0.120 |
Why?
| | DNA, Intergenic | 1 | 2016 | 25 | 0.120 |
Why?
| | Cyclooxygenase 1 | 2 | 2014 | 27 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2020 | 561 | 0.120 |
Why?
| | Enhancer Elements, Genetic | 1 | 2017 | 190 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 1 | 2019 | 486 | 0.120 |
Why?
| | Carotid Artery Diseases | 1 | 2016 | 70 | 0.120 |
Why?
| | Schistosomiasis | 1 | 2017 | 54 | 0.120 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2023 | 640 | 0.120 |
Why?
| | Erythropoiesis | 1 | 2016 | 57 | 0.120 |
Why?
| | White Matter | 1 | 2018 | 169 | 0.120 |
Why?
| | Mitochondrial Proteins | 1 | 2018 | 263 | 0.120 |
Why?
| | Immune System Diseases | 1 | 2016 | 43 | 0.120 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2017 | 176 | 0.120 |
Why?
| | Lipoprotein(a) | 1 | 2016 | 70 | 0.110 |
Why?
| | Myocardial Infarction | 2 | 2020 | 1215 | 0.110 |
Why?
| | Severity of Illness Index | 5 | 2019 | 2921 | 0.110 |
Why?
| | Anthropometry | 2 | 2022 | 204 | 0.110 |
Why?
| | Sexism | 1 | 2016 | 70 | 0.110 |
Why?
| | Kidney Transplantation | 2 | 2012 | 735 | 0.110 |
Why?
| | Cell Differentiation | 2 | 2021 | 1982 | 0.110 |
Why?
| | Decision Support Systems, Clinical | 1 | 2020 | 279 | 0.110 |
Why?
| | Lung Diseases, Interstitial | 1 | 2022 | 677 | 0.110 |
Why?
| | Genes, Modifier | 1 | 2015 | 2 | 0.110 |
Why?
| | Leukocytes, Mononuclear | 2 | 2021 | 585 | 0.110 |
Why?
| | Caveolin 2 | 1 | 2015 | 3 | 0.110 |
Why?
| | Factor VII | 1 | 2015 | 24 | 0.110 |
Why?
| | CpG Islands | 3 | 2023 | 175 | 0.110 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 178 | 0.110 |
Why?
| | Molecular Sequence Annotation | 3 | 2021 | 110 | 0.110 |
Why?
| | Receptors, Interferon | 1 | 2015 | 60 | 0.110 |
Why?
| | United Kingdom | 3 | 2021 | 377 | 0.110 |
Why?
| | Collagen | 2 | 2015 | 460 | 0.110 |
Why?
| | Schistosomiasis japonica | 1 | 2015 | 37 | 0.110 |
Why?
| | Interleukin-10 | 2 | 2017 | 310 | 0.110 |
Why?
| | Minority Groups | 1 | 2017 | 286 | 0.110 |
Why?
| | Adenosine Triphosphatases | 1 | 2016 | 158 | 0.110 |
Why?
| | Mutation Rate | 1 | 2015 | 37 | 0.110 |
Why?
| | Scleroderma, Systemic | 1 | 2016 | 124 | 0.110 |
Why?
| | Mutant Chimeric Proteins | 1 | 2014 | 5 | 0.110 |
Why?
| | KCNQ1 Potassium Channel | 1 | 2014 | 8 | 0.110 |
Why?
| | Menopause | 2 | 2023 | 328 | 0.110 |
Why?
| | HLA-B27 Antigen | 1 | 2014 | 16 | 0.110 |
Why?
| | HMGA2 Protein | 1 | 2014 | 10 | 0.110 |
Why?
| | Hypertension | 2 | 2022 | 1272 | 0.110 |
Why?
| | Chromosome Disorders | 1 | 2014 | 46 | 0.110 |
Why?
| | Transcription Factor 7-Like 2 Protein | 1 | 2014 | 26 | 0.100 |
Why?
| | Machine Learning | 3 | 2025 | 594 | 0.100 |
Why?
| | Cells, Cultured | 2 | 2021 | 4118 | 0.100 |
Why?
| | Rhinitis, Allergic | 1 | 2014 | 41 | 0.100 |
Why?
| | Family Health | 4 | 2011 | 194 | 0.100 |
Why?
| | Tobacco Use Disorder | 2 | 2013 | 217 | 0.100 |
Why?
| | Transmembrane Activator and CAML Interactor Protein | 1 | 2013 | 4 | 0.100 |
Why?
| | Cystic Fibrosis | 2 | 2015 | 1164 | 0.100 |
Why?
| | beta-Defensins | 1 | 2013 | 22 | 0.100 |
Why?
| | Body Mass Index | 5 | 2022 | 2458 | 0.100 |
Why?
| | Vital Capacity | 1 | 2014 | 293 | 0.100 |
Why?
| | Family Practice | 1 | 1997 | 422 | 0.100 |
Why?
| | Obesity | 2 | 2022 | 3131 | 0.100 |
Why?
| | Exercise | 1 | 2025 | 2213 | 0.100 |
Why?
| | Chronic Kidney Disease-Mineral and Bone Disorder | 1 | 1993 | 14 | 0.100 |
Why?
| | Kv Channel-Interacting Proteins | 1 | 2013 | 2 | 0.100 |
Why?
| | Dietary Supplements | 1 | 2017 | 587 | 0.100 |
Why?
| | Chemokine CXCL12 | 1 | 2013 | 85 | 0.100 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 2011 | 82 | 0.100 |
Why?
| | Professional Impairment | 1 | 1993 | 3 | 0.100 |
Why?
| | Virginia | 2 | 2005 | 57 | 0.090 |
Why?
| | Pseudomonas aeruginosa | 2 | 2015 | 392 | 0.090 |
Why?
| | Dentists | 1 | 1993 | 21 | 0.090 |
Why?
| | Genetic Markers | 5 | 2016 | 340 | 0.090 |
Why?
| | HEK293 Cells | 3 | 2021 | 750 | 0.090 |
Why?
| | Longitudinal Studies | 5 | 2021 | 3017 | 0.090 |
Why?
| | Stroke | 1 | 2022 | 1287 | 0.090 |
Why?
| | Microbiota | 1 | 2020 | 725 | 0.090 |
Why?
| | Skin Tests | 4 | 2017 | 94 | 0.090 |
Why?
| | Principal Component Analysis | 2 | 2010 | 192 | 0.090 |
Why?
| | K562 Cells | 2 | 2024 | 93 | 0.090 |
Why?
| | Hepatocyte Nuclear Factor 3-alpha | 1 | 2012 | 9 | 0.090 |
Why?
| | Ankyrins | 1 | 2012 | 11 | 0.090 |
Why?
| | Kallikreins | 1 | 2012 | 25 | 0.090 |
Why?
| | Parents | 3 | 2007 | 1394 | 0.090 |
Why?
| | Duffy Blood-Group System | 2 | 2011 | 6 | 0.090 |
Why?
| | Critical Care | 1 | 2019 | 706 | 0.090 |
Why?
| | Phylogeny | 1 | 2016 | 924 | 0.090 |
Why?
| | Nuclear Proteins | 1 | 2017 | 740 | 0.090 |
Why?
| | Fatty Acids | 1 | 2015 | 460 | 0.090 |
Why?
| | Respiratory Sounds | 1 | 2012 | 102 | 0.090 |
Why?
| | Triglycerides | 3 | 2015 | 527 | 0.090 |
Why?
| | Hepatitis B | 1 | 1993 | 66 | 0.090 |
Why?
| | Leukocyte Count | 2 | 2011 | 321 | 0.090 |
Why?
| | Education, Medical, Graduate | 1 | 1997 | 568 | 0.090 |
Why?
| | Mitochondria | 1 | 2018 | 997 | 0.090 |
Why?
| | Dioxygenases | 2 | 2023 | 36 | 0.090 |
Why?
| | Prostate-Specific Antigen | 1 | 2012 | 162 | 0.090 |
Why?
| | Steroids | 1 | 2012 | 160 | 0.080 |
Why?
| | Heterozygote | 3 | 2021 | 311 | 0.080 |
Why?
| | Microtubule-Associated Proteins | 1 | 2012 | 187 | 0.080 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2011 | 14 | 0.080 |
Why?
| | Insulin | 4 | 2022 | 2525 | 0.080 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2011 | 36 | 0.080 |
Why?
| | Patients | 1 | 1993 | 183 | 0.080 |
Why?
| | Aquaporin 5 | 1 | 2010 | 3 | 0.080 |
Why?
| | Gene Expression Profiling | 2 | 2025 | 1792 | 0.080 |
Why?
| | Reproducibility of Results | 6 | 2021 | 3416 | 0.080 |
Why?
| | Heredity | 2 | 2021 | 13 | 0.080 |
Why?
| | Disease Progression | 5 | 2019 | 2867 | 0.080 |
Why?
| | Chromosomes | 1 | 2011 | 105 | 0.080 |
Why?
| | Mice | 11 | 2023 | 18297 | 0.080 |
Why?
| | Cockroaches | 1 | 2010 | 23 | 0.080 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2010 | 30 | 0.080 |
Why?
| | Age Factors | 4 | 2026 | 3347 | 0.080 |
Why?
| | Recombination, Genetic | 1 | 2011 | 202 | 0.080 |
Why?
| | Death Domain Receptor Signaling Adaptor Proteins | 1 | 2009 | 2 | 0.080 |
Why?
| | Curriculum | 1 | 1997 | 1079 | 0.080 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 1 | 2010 | 36 | 0.080 |
Why?
| | Eosinophils | 2 | 2025 | 319 | 0.080 |
Why?
| | Lectins | 1 | 2010 | 44 | 0.080 |
Why?
| | Incidence | 4 | 2019 | 2936 | 0.070 |
Why?
| | Myocardial Ischemia | 1 | 2011 | 286 | 0.070 |
Why?
| | Nuclear Family | 2 | 2007 | 51 | 0.070 |
Why?
| | Isoenzymes | 1 | 2010 | 294 | 0.070 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2009 | 64 | 0.070 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2009 | 76 | 0.070 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2009 | 14 | 0.070 |
Why?
| | Interviews as Topic | 2 | 2006 | 930 | 0.070 |
Why?
| | Chromosomes, Human | 1 | 2009 | 45 | 0.070 |
Why?
| | Tryptophan | 1 | 2010 | 184 | 0.070 |
Why?
| | Arginine | 1 | 2010 | 264 | 0.070 |
Why?
| | Caribbean Region | 4 | 2011 | 29 | 0.070 |
Why?
| | Confidence Intervals | 2 | 2014 | 329 | 0.070 |
Why?
| | Receptors, Leptin | 1 | 2009 | 25 | 0.070 |
Why?
| | Renal Dialysis | 1 | 1993 | 461 | 0.070 |
Why?
| | Interferon-alpha | 1 | 2010 | 201 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3926 | 0.070 |
Why?
| | Graft Rejection | 1 | 2012 | 516 | 0.070 |
Why?
| | Agammaglobulinemia | 1 | 1989 | 36 | 0.070 |
Why?
| | Regression Analysis | 3 | 2025 | 999 | 0.070 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2009 | 54 | 0.070 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2022 | 372 | 0.070 |
Why?
| | Nephrotic Syndrome | 1 | 1989 | 44 | 0.070 |
Why?
| | Proto-Oncogene Proteins | 2 | 2023 | 616 | 0.070 |
Why?
| | Health Services Accessibility | 1 | 2017 | 1107 | 0.070 |
Why?
| | Thromboxane B2 | 3 | 2018 | 23 | 0.070 |
Why?
| | Proteoglycans | 1 | 2009 | 111 | 0.070 |
Why?
| | Genotyping Techniques | 2 | 2019 | 74 | 0.070 |
Why?
| | Cholesterol | 2 | 2015 | 411 | 0.070 |
Why?
| | Siblings | 2 | 2011 | 202 | 0.070 |
Why?
| | Polymerase Chain Reaction | 2 | 2012 | 1031 | 0.070 |
Why?
| | Chromosomes, Human, Pair 17 | 3 | 2019 | 54 | 0.070 |
Why?
| | Alcoholism | 3 | 2005 | 830 | 0.070 |
Why?
| | Research Design | 2 | 2019 | 1143 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 829 | 0.060 |
Why?
| | Myosin-Light-Chain Kinase | 1 | 2007 | 19 | 0.060 |
Why?
| | British Columbia | 3 | 1997 | 27 | 0.060 |
Why?
| | Age of Onset | 3 | 2013 | 558 | 0.060 |
Why?
| | Inheritance Patterns | 1 | 2006 | 49 | 0.060 |
Why?
| | Cognition | 1 | 2015 | 1292 | 0.060 |
Why?
| | Databases, Factual | 1 | 2012 | 1493 | 0.060 |
Why?
| | Thrombophilia | 1 | 2007 | 89 | 0.060 |
Why?
| | Antigens, CD | 1 | 2010 | 560 | 0.060 |
Why?
| | Deoxyribonuclease HindIII | 1 | 2006 | 2 | 0.060 |
Why?
| | Infant, Newborn | 6 | 2012 | 6460 | 0.060 |
Why?
| | alpha-Linolenic Acid | 2 | 2017 | 8 | 0.060 |
Why?
| | Meta-Analysis as Topic | 3 | 2012 | 173 | 0.060 |
Why?
| | Adenosine Diphosphate | 2 | 2017 | 75 | 0.060 |
Why?
| | Europe | 2 | 2020 | 421 | 0.060 |
Why?
| | Neoplasm Proteins | 2 | 2022 | 444 | 0.060 |
Why?
| | Chromosomes, Human, Pair 4 | 2 | 2019 | 26 | 0.060 |
Why?
| | Platelet Count | 2 | 2016 | 95 | 0.060 |
Why?
| | Registries | 1 | 2014 | 2400 | 0.060 |
Why?
| | DNA Mutational Analysis | 2 | 2020 | 410 | 0.060 |
Why?
| | Prospective Studies | 5 | 2020 | 8123 | 0.060 |
Why?
| | Epinephrine | 2 | 2017 | 160 | 0.060 |
Why?
| | Glucose | 2 | 2022 | 1053 | 0.060 |
Why?
| | Ozone | 1 | 2006 | 116 | 0.050 |
Why?
| | Transfection | 3 | 2016 | 916 | 0.050 |
Why?
| | Receptors, Prostaglandin | 1 | 2004 | 21 | 0.050 |
Why?
| | Mucins | 1 | 2005 | 75 | 0.050 |
Why?
| | ABO Blood-Group System | 1 | 2025 | 56 | 0.050 |
Why?
| | Complement C3 | 1 | 2006 | 195 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2005 | 162 | 0.050 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2024 | 26 | 0.050 |
Why?
| | Mites | 1 | 2004 | 7 | 0.050 |
Why?
| | Janus Kinase 2 | 1 | 2024 | 31 | 0.050 |
Why?
| | Loss of Heterozygosity | 1 | 2024 | 51 | 0.050 |
Why?
| | National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2024 | 25 | 0.050 |
Why?
| | Hypertension, Pulmonary | 1 | 2016 | 1957 | 0.050 |
Why?
| | Gene Targeting | 2 | 2020 | 76 | 0.050 |
Why?
| | Eye Proteins | 2 | 2021 | 93 | 0.050 |
Why?
| | Kidney | 2 | 2023 | 1498 | 0.050 |
Why?
| | Matched-Pair Analysis | 1 | 2003 | 38 | 0.050 |
Why?
| | Chromosomes, Human, Pair 14 | 2 | 2014 | 23 | 0.050 |
Why?
| | Adult Children | 1 | 2003 | 27 | 0.050 |
Why?
| | Time | 1 | 2003 | 85 | 0.050 |
Why?
| | Interleukin-6 | 2 | 2024 | 784 | 0.050 |
Why?
| | Epigenomics | 1 | 2024 | 124 | 0.050 |
Why?
| | Receptors, Complement | 1 | 2004 | 126 | 0.050 |
Why?
| | Guanine Nucleotide Dissociation Inhibitors | 1 | 2023 | 2 | 0.050 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2024 | 106 | 0.050 |
Why?
| | Societies, Medical | 2 | 2019 | 907 | 0.050 |
Why?
| | Genes | 1 | 2003 | 215 | 0.050 |
Why?
| | Disease Models, Animal | 1 | 2014 | 4580 | 0.050 |
Why?
| | Diabetic Retinopathy | 1 | 2006 | 211 | 0.050 |
Why?
| | Environment | 2 | 2010 | 299 | 0.050 |
Why?
| | Sulfites | 1 | 2023 | 8 | 0.050 |
Why?
| | Sex Factors | 3 | 2014 | 2107 | 0.050 |
Why?
| | Eosinophilia | 2 | 2023 | 224 | 0.050 |
Why?
| | Aminopeptidases | 1 | 2023 | 20 | 0.050 |
Why?
| | Disease Susceptibility | 3 | 2014 | 339 | 0.050 |
Why?
| | Membrane Glycoproteins | 2 | 2005 | 495 | 0.050 |
Why?
| | Cell Line | 3 | 2015 | 2814 | 0.050 |
Why?
| | Genes, Reporter | 2 | 2015 | 275 | 0.050 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2022 | 15 | 0.050 |
Why?
| | Pruritus | 1 | 2023 | 61 | 0.050 |
Why?
| | CRISPR-Cas Systems | 1 | 2024 | 163 | 0.050 |
Why?
| | Cooperative Behavior | 1 | 2005 | 471 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2016 | 2791 | 0.050 |
Why?
| | Frail Elderly | 1 | 2023 | 141 | 0.050 |
Why?
| | Syndrome | 1 | 2023 | 380 | 0.050 |
Why?
| | Fruit | 1 | 2023 | 144 | 0.050 |
Why?
| | Vegetables | 1 | 2023 | 159 | 0.040 |
Why?
| | Electroencephalography | 1 | 2005 | 576 | 0.040 |
Why?
| | Risk Assessment | 2 | 2025 | 3712 | 0.040 |
Why?
| | Nutrition Surveys | 1 | 2023 | 270 | 0.040 |
Why?
| | Colorado | 2 | 2024 | 4595 | 0.040 |
Why?
| | RGS Proteins | 1 | 2021 | 17 | 0.040 |
Why?
| | Internationality | 2 | 2013 | 156 | 0.040 |
Why?
| | Chromatin | 1 | 2025 | 559 | 0.040 |
Why?
| | Subcutaneous Tissue | 1 | 2021 | 26 | 0.040 |
Why?
| | INDEL Mutation | 1 | 2021 | 21 | 0.040 |
Why?
| | Colombia | 2 | 2013 | 41 | 0.040 |
Why?
| | Antigens, Protozoan | 1 | 2001 | 32 | 0.040 |
Why?
| | Antibodies, Protozoan | 1 | 2001 | 41 | 0.040 |
Why?
| | Postmenopause | 1 | 2023 | 394 | 0.040 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2021 | 33 | 0.040 |
Why?
| | alpha Karyopherins | 1 | 2020 | 10 | 0.040 |
Why?
| | Receptors, LDL | 1 | 2020 | 53 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2021 | 120 | 0.040 |
Why?
| | Antibodies, Heterophile | 1 | 2000 | 12 | 0.040 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2021 | 92 | 0.040 |
Why?
| | Lymphocytosis | 1 | 2000 | 12 | 0.040 |
Why?
| | Cricetinae | 1 | 2001 | 296 | 0.040 |
Why?
| | Population Density | 1 | 2021 | 91 | 0.040 |
Why?
| | GTP-Binding Proteins | 1 | 2021 | 150 | 0.040 |
Why?
| | Tripartite Motif Proteins | 1 | 2020 | 39 | 0.040 |
Why?
| | Sample Size | 1 | 2021 | 124 | 0.040 |
Why?
| | Lod Score | 3 | 2009 | 64 | 0.040 |
Why?
| | Sepsis | 1 | 2007 | 669 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2021 | 84 | 0.040 |
Why?
| | Cell Self Renewal | 1 | 2020 | 50 | 0.040 |
Why?
| | Eating | 1 | 2023 | 386 | 0.040 |
Why?
| | Prognosis | 2 | 2021 | 4351 | 0.040 |
Why?
| | Names | 1 | 2000 | 15 | 0.040 |
Why?
| | Pneumonia | 1 | 2006 | 635 | 0.040 |
Why?
| | Respiratory Function Tests | 2 | 2013 | 543 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2006 | 844 | 0.040 |
Why?
| | Lens, Crystalline | 1 | 2001 | 136 | 0.040 |
Why?
| | Gene Editing | 1 | 2021 | 89 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C19 | 1 | 2020 | 29 | 0.040 |
Why?
| | Mutagenesis | 1 | 2021 | 196 | 0.040 |
Why?
| | Mucin-5B | 1 | 2022 | 234 | 0.040 |
Why?
| | Gene Silencing | 1 | 2020 | 200 | 0.040 |
Why?
| | A549 Cells | 1 | 2019 | 76 | 0.040 |
Why?
| | North America | 2 | 2011 | 300 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2023 | 430 | 0.040 |
Why?
| | Time Factors | 3 | 2019 | 7109 | 0.040 |
Why?
| | Body Weight | 1 | 2003 | 968 | 0.040 |
Why?
| | Fibrinolysis | 1 | 2021 | 162 | 0.040 |
Why?
| | Siberia | 1 | 2019 | 7 | 0.040 |
Why?
| | Emigration and Immigration | 1 | 2000 | 67 | 0.040 |
Why?
| | Up-Regulation | 2 | 2016 | 841 | 0.040 |
Why?
| | Flame Ionization | 1 | 2019 | 2 | 0.040 |
Why?
| | Information Dissemination | 1 | 2021 | 226 | 0.040 |
Why?
| | Linear Models | 2 | 2017 | 857 | 0.040 |
Why?
| | Cloud Computing | 1 | 2019 | 6 | 0.040 |
Why?
| | Recombinases | 1 | 2019 | 10 | 0.040 |
Why?
| | Event-Related Potentials, P300 | 1 | 1999 | 17 | 0.040 |
Why?
| | Waist-Hip Ratio | 1 | 2018 | 37 | 0.040 |
Why?
| | Monoamine Oxidase | 1 | 1999 | 27 | 0.040 |
Why?
| | Cataract | 1 | 2001 | 240 | 0.040 |
Why?
| | Chromosomes, Human, Pair 8 | 1 | 2019 | 41 | 0.040 |
Why?
| | Antibodies, Viral | 2 | 2000 | 689 | 0.040 |
Why?
| | Limit of Detection | 1 | 2019 | 92 | 0.030 |
Why?
| | Proportional Hazards Models | 2 | 2014 | 1331 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2022 | 630 | 0.030 |
Why?
| | RNA Splicing Factors | 1 | 2019 | 66 | 0.030 |
Why?
| | Calibration | 1 | 2019 | 154 | 0.030 |
Why?
| | Prevalence | 2 | 2016 | 2861 | 0.030 |
Why?
| | Reference Standards | 1 | 2019 | 176 | 0.030 |
Why?
| | Organ Size | 1 | 2019 | 465 | 0.030 |
Why?
| | Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2018 | 10 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2019 | 567 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 2 | 2019 | 2537 | 0.030 |
Why?
| | Skin | 1 | 2023 | 701 | 0.030 |
Why?
| | Virus Diseases | 1 | 2000 | 219 | 0.030 |
Why?
| | Rhinitis, Allergic, Seasonal | 1 | 2017 | 25 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2024 | 876 | 0.030 |
Why?
| | Double-Blind Method | 2 | 2020 | 2070 | 0.030 |
Why?
| | Histone Code | 1 | 2017 | 39 | 0.030 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 457 | 0.030 |
Why?
| | Rubella Vaccine | 1 | 1997 | 7 | 0.030 |
Why?
| | Program Evaluation | 1 | 2021 | 952 | 0.030 |
Why?
| | Adipocytes | 1 | 2018 | 223 | 0.030 |
Why?
| | Rubella | 1 | 1997 | 23 | 0.030 |
Why?
| | HIV Infections | 1 | 1993 | 3215 | 0.030 |
Why?
| | Apolipoprotein E2 | 1 | 2016 | 4 | 0.030 |
Why?
| | Apolipoprotein B-100 | 1 | 2016 | 13 | 0.030 |
Why?
| | Selection, Genetic | 1 | 2019 | 269 | 0.030 |
Why?
| | Interleukin-33 | 1 | 2017 | 45 | 0.030 |
Why?
| | GPI-Linked Proteins | 1 | 2017 | 81 | 0.030 |
Why?
| | Demography | 1 | 2017 | 274 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2018 | 496 | 0.030 |
Why?
| | Preceptorship | 1 | 1997 | 68 | 0.030 |
Why?
| | Data Accuracy | 1 | 2017 | 64 | 0.030 |
Why?
| | Workflow | 1 | 2018 | 182 | 0.030 |
Why?
| | Denmark | 1 | 2016 | 51 | 0.030 |
Why?
| | Mean Platelet Volume | 1 | 2016 | 3 | 0.030 |
Why?
| | Allelic Imbalance | 1 | 2016 | 8 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2005 | 2012 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2019 | 253 | 0.030 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2016 | 75 | 0.030 |
Why?
| | Erythrocyte Indices | 1 | 2016 | 33 | 0.030 |
Why?
| | Massachusetts | 1 | 2017 | 178 | 0.030 |
Why?
| | Blood Cell Count | 1 | 2016 | 56 | 0.030 |
Why?
| | Neoplasms | 1 | 2012 | 2954 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2019 | 5439 | 0.030 |
Why?
| | Hematocrit | 1 | 2016 | 108 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 102 | 0.030 |
Why?
| | DNA | 1 | 2023 | 1421 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1888 | 0.030 |
Why?
| | China | 1 | 2017 | 280 | 0.030 |
Why?
| | Stearic Acids | 1 | 2015 | 15 | 0.030 |
Why?
| | Sarcoglycans | 1 | 2015 | 5 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 297 | 0.030 |
Why?
| | Bias | 1 | 2016 | 197 | 0.030 |
Why?
| | Lung Volume Measurements | 1 | 2015 | 44 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1543 | 0.030 |
Why?
| | Protein Transport | 1 | 2017 | 443 | 0.030 |
Why?
| | Computed Tomography Angiography | 1 | 2016 | 151 | 0.030 |
Why?
| | STAT1 Transcription Factor | 1 | 2015 | 68 | 0.030 |
Why?
| | Vascular Calcification | 1 | 2016 | 109 | 0.030 |
Why?
| | HTLV-I Infections | 1 | 1995 | 29 | 0.030 |
Why?
| | Social Class | 1 | 2017 | 260 | 0.030 |
Why?
| | Glucose-6-Phosphatase | 1 | 2015 | 32 | 0.030 |
Why?
| | Nutritional Status | 1 | 2017 | 346 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2016 | 334 | 0.030 |
Why?
| | Phosphoproteins | 1 | 2017 | 320 | 0.030 |
Why?
| | Mice, Knockout | 3 | 2009 | 3125 | 0.030 |
Why?
| | Coronary Angiography | 1 | 2016 | 325 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 2014 | 37 | 0.030 |
Why?
| | Potassium Channels | 1 | 2015 | 149 | 0.030 |
Why?
| | Pneumothorax | 1 | 2014 | 54 | 0.030 |
Why?
| | Host-Parasite Interactions | 1 | 2015 | 109 | 0.030 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2015 | 88 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2022 | 0.030 |
Why?
| | Myosin Heavy Chains | 1 | 2015 | 177 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2019 | 902 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 568 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2018 | 442 | 0.030 |
Why?
| | Hemoglobins | 1 | 2016 | 384 | 0.020 |
Why?
| | Health Policy | 1 | 2017 | 399 | 0.020 |
Why?
| | Diet, Western | 1 | 2014 | 89 | 0.020 |
Why?
| | alpha 1-Antitrypsin | 1 | 2014 | 104 | 0.020 |
Why?
| | Stress, Psychological | 1 | 2022 | 1171 | 0.020 |
Why?
| | Deferoxamine | 1 | 1993 | 27 | 0.020 |
Why?
| | Jamaica | 1 | 2013 | 9 | 0.020 |
Why?
| | Cotinine | 1 | 2013 | 77 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2014 | 175 | 0.020 |
Why?
| | District of Columbia | 1 | 2013 | 37 | 0.020 |
Why?
| | Societies, Dental | 1 | 1993 | 2 | 0.020 |
Why?
| | Aluminum | 1 | 1993 | 43 | 0.020 |
Why?
| | Gene Order | 1 | 2012 | 29 | 0.020 |
Why?
| | Educational Status | 1 | 2015 | 466 | 0.020 |
Why?
| | New York | 1 | 2013 | 128 | 0.020 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2012 | 21 | 0.020 |
Why?
| | Dynactin Complex | 1 | 2012 | 5 | 0.020 |
Why?
| | Immunity, Mucosal | 1 | 2013 | 97 | 0.020 |
Why?
| | Parathyroid Hormone | 1 | 1993 | 118 | 0.020 |
Why?
| | Organizational Policy | 1 | 1993 | 76 | 0.020 |
Why?
| | Untranslated Regions | 1 | 2012 | 3 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2009 | 6073 | 0.020 |
Why?
| | Adolescent Development | 1 | 2012 | 72 | 0.020 |
Why?
| | Statistics, Nonparametric | 2 | 2005 | 426 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 970 | 0.020 |
Why?
| | Wales | 1 | 2011 | 24 | 0.020 |
Why?
| | Chemokine CXCL2 | 1 | 2011 | 41 | 0.020 |
Why?
| | England | 1 | 2011 | 106 | 0.020 |
Why?
| | Epidemiologic Methods | 1 | 2011 | 91 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2014 | 508 | 0.020 |
Why?
| | Canada | 1 | 2012 | 432 | 0.020 |
Why?
| | Biological Evolution | 1 | 2015 | 471 | 0.020 |
Why?
| | X Chromosome Inactivation | 1 | 2011 | 25 | 0.020 |
Why?
| | Eicosapentaenoic Acid | 1 | 2011 | 37 | 0.020 |
Why?
| | Luciferases | 1 | 2011 | 153 | 0.020 |
Why?
| | Microsatellite Repeats | 2 | 2003 | 159 | 0.020 |
Why?
| | Costa Rica | 1 | 2010 | 18 | 0.020 |
Why?
| | Pulmonary Fibrosis | 1 | 2014 | 395 | 0.020 |
Why?
| | Chronic Disease | 1 | 2017 | 1827 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2015 | 728 | 0.020 |
Why?
| | Salmeterol Xinafoate | 1 | 2010 | 20 | 0.020 |
Why?
| | Overweight | 1 | 2015 | 614 | 0.020 |
Why?
| | Age Distribution | 1 | 2011 | 399 | 0.020 |
Why?
| | Artifacts | 1 | 2011 | 143 | 0.020 |
Why?
| | Iron | 1 | 1993 | 359 | 0.020 |
Why?
| | Sex Distribution | 1 | 2011 | 382 | 0.020 |
Why?
| | Codon, Nonsense | 1 | 2010 | 46 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2011 | 136 | 0.020 |
Why?
| | Introns | 1 | 2011 | 257 | 0.020 |
Why?
| | Bone and Bones | 1 | 1993 | 319 | 0.020 |
Why?
| | Albuterol | 1 | 2010 | 76 | 0.020 |
Why?
| | Markov Chains | 1 | 2010 | 129 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1298 | 0.020 |
Why?
| | Biopsy | 1 | 1993 | 1075 | 0.020 |
Why?
| | Kainic Acid | 1 | 2009 | 33 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2010 | 245 | 0.020 |
Why?
| | Nicotine | 1 | 2012 | 337 | 0.020 |
Why?
| | Waist Circumference | 1 | 2010 | 142 | 0.020 |
Why?
| | Plasmids | 1 | 2010 | 373 | 0.020 |
Why?
| | Excitatory Amino Acid Agonists | 1 | 2009 | 42 | 0.020 |
Why?
| | Acute Disease | 1 | 2012 | 1038 | 0.020 |
Why?
| | Urban Population | 1 | 2012 | 497 | 0.020 |
Why?
| | DNA Replication | 1 | 2011 | 248 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2009 | 162 | 0.020 |
Why?
| | Bronchodilator Agents | 1 | 2010 | 186 | 0.020 |
Why?
| | Disease | 1 | 2009 | 97 | 0.020 |
Why?
| | Hospitals | 1 | 1993 | 738 | 0.020 |
Why?
| | Spirometry | 1 | 2009 | 234 | 0.020 |
Why?
| | Korea | 1 | 2007 | 18 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1998 | 0.020 |
Why?
| | beta-Thromboglobulin | 1 | 2007 | 3 | 0.020 |
Why?
| | Quality of Life | 1 | 2019 | 3200 | 0.020 |
Why?
| | Binding Sites | 1 | 2010 | 1309 | 0.020 |
Why?
| | Dendritic Cells | 1 | 2010 | 509 | 0.020 |
Why?
| | Drug Resistance | 1 | 2007 | 145 | 0.020 |
Why?
| | Transcription Factors | 1 | 2014 | 1730 | 0.010 |
Why?
| | Models, Theoretical | 1 | 2009 | 561 | 0.010 |
Why?
| | Receptor for Advanced Glycation End Products | 1 | 2006 | 36 | 0.010 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2005 | 43 | 0.010 |
Why?
| | Genetic Testing | 2 | 1999 | 492 | 0.010 |
Why?
| | False Positive Reactions | 1 | 2005 | 124 | 0.010 |
Why?
| | Hepatitis A Antibodies | 1 | 2005 | 3 | 0.010 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2005 | 27 | 0.010 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2005 | 42 | 0.010 |
Why?
| | Hepatitis A | 1 | 2005 | 25 | 0.010 |
Why?
| | Receptors, Virus | 1 | 2005 | 91 | 0.010 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 2004 | 26 | 0.010 |
Why?
| | Seroepidemiologic Studies | 1 | 2005 | 171 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2009 | 1712 | 0.010 |
Why?
| | Antigens, Dermatophagoides | 1 | 2004 | 10 | 0.010 |
Why?
| | U937 Cells | 1 | 2004 | 28 | 0.010 |
Why?
| | Chromosomes, Human, Pair 20 | 1 | 2004 | 17 | 0.010 |
Why?
| | Gene Deletion | 1 | 2006 | 385 | 0.010 |
Why?
| | NIH 3T3 Cells | 1 | 2004 | 147 | 0.010 |
Why?
| | Receptor, Anaphylatoxin C5a | 1 | 2004 | 35 | 0.010 |
Why?
| | Germany | 1 | 2004 | 139 | 0.010 |
Why?
| | 3' Untranslated Regions | 1 | 2004 | 152 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2018 | 11821 | 0.010 |
Why?
| | Pulmonary Alveoli | 1 | 2006 | 385 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2006 | 1244 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2007 | 384 | 0.010 |
Why?
| | Kinetics | 1 | 2006 | 1553 | 0.010 |
Why?
| | Aquaporins | 1 | 2001 | 8 | 0.010 |
Why?
| | Osmosis | 1 | 2001 | 22 | 0.010 |
Why?
| | Chimera | 1 | 2001 | 62 | 0.010 |
Why?
| | Crosses, Genetic | 1 | 2001 | 120 | 0.010 |
Why?
| | Optics and Photonics | 1 | 2001 | 38 | 0.010 |
Why?
| | Permeability | 1 | 2001 | 166 | 0.010 |
Why?
| | Lasers | 1 | 2001 | 127 | 0.010 |
Why?
| | Western Australia | 1 | 2001 | 8 | 0.010 |
Why?
| | HIV-2 | 1 | 2000 | 18 | 0.010 |
Why?
| | Cost Control | 1 | 2000 | 38 | 0.010 |
Why?
| | Herpesvirus 6, Human | 1 | 2000 | 14 | 0.010 |
Why?
| | Toxoplasma | 1 | 2000 | 50 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2004 | 2838 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 2000 | 172 | 0.010 |
Why?
| | Expert Testimony | 1 | 1999 | 43 | 0.010 |
Why?
| | Cytomegalovirus | 1 | 2000 | 172 | 0.010 |
Why?
| | Immunoglobulin M | 1 | 2000 | 284 | 0.010 |
Why?
| | Observer Variation | 1 | 1999 | 356 | 0.010 |
Why?
| | Lymphocytes | 1 | 2000 | 379 | 0.010 |
Why?
| | Water | 1 | 2001 | 451 | 0.010 |
Why?
| | Rats | 1 | 2006 | 5586 | 0.010 |
Why?
| | Rubella virus | 1 | 1997 | 7 | 0.010 |
Why?
| | Paresthesia | 1 | 1997 | 14 | 0.010 |
Why?
| | Arthralgia | 1 | 1997 | 66 | 0.010 |
Why?
| | Vaccines, Attenuated | 1 | 1997 | 129 | 0.010 |
Why?
| | Muscular Diseases | 1 | 1997 | 110 | 0.010 |
Why?
| | Arthritis | 1 | 1997 | 97 | 0.010 |
Why?
| | HIV-1 | 1 | 2000 | 913 | 0.010 |
Why?
| | Postpartum Period | 1 | 1997 | 377 | 0.010 |
Why?
| | Pain | 1 | 1997 | 790 | 0.010 |
Why?
| | Physicians | 1 | 1999 | 955 | 0.010 |
Why?
| | Vaccination | 1 | 1997 | 1449 | 0.000 |
Why?
|
|
Mathias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|